China Resources Double-Crane Completes Phase III Trial for Pregabalin Extended-Release Tablets

Product / Tech
โดย CLS·CN·Read original
Summary · why it matters

China Resources Double-Crane announced that its wholly-owned subsidiary Double-Crane Limin has completed the registration and public disclosure of the Phase III clinical trial for pregabalin extended-release tablets. The trial evaluated the efficacy and safety of the drug in treating postherpetic neuralgia, with conclusions showing clear efficacy, rapid onset, stable long-term efficacy, and good safety. The drug is a gamma-aminobutyric acid receptor blocker, and currently only Jiangsu Hengrui Medicine has been approved for marketing in China. As of the announcement date, cumulative R&D investment reached 27.3547 million yuan.

Impact on stocks 3

Others± Mixed · 3 stocks

Off-coverage companies 1

双鹤利民Private▲ Positive
Technologyrelevance

Subsidiary completed the Phase III trial, contributing to parent's pipeline.

© 2026 MarketDXNews